← Back to patent-cliff list
丙酸氟替卡松/富马酸福莫特罗
Tier C — Watch / tradeFluticasone Propionate/Formoterol Fumarate Hydrate
Ranbaxy Inc
Originator
2006
First approval
-
Expiry (public)
$0.13B ▲
Peak sales
化学药
Type
Targets：ADRB2、GR、PLA2G4A
Brand：Flutiform、Flutiform K-haler、Avessa
Indications (approved)：哮喘
Regional status
US
无进展
2008-09-01
EU
无进展
2007-03-01
China
批准上市
2023-09-12
Japan
批准上市
2013-09-20
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Fluticasone Propionate/Formoterol Fumarate Hydrate?
Approved indications include: 哮喘.
When does the Fluticasone Propionate/Formoterol Fumarate Hydrate patent expire?
No public expiry year is available for Fluticasone Propionate/Formoterol Fumarate Hydrate yet; this page updates once verified.
How do I get a quote for Fluticasone Propionate/Formoterol Fumarate Hydrate intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-24